(1)
LUND, Sweden, Jan. 13, 2021(publ) (CLS), a developer of advanced innovative products for high-precision, image-guided laser ablation, today announced that the company has strengthened its organization by hiring new team members in key positions. CLS names Lotta Ljungberg as VP of Regulatory Affairs & Quality Assurance and Hoda Tawfik as VP of Clinical Affairs.
Lotta Ljungberg holds a Master of Science from Lund University and was previously Head of Quality Assurance at Biora. Hoda Tawfik has a PhD from University of Cairo, Department of Pharmacology, and held a position as CMO/COO at Magforce Nanomedicine up until the start of her own consultancy business in 2020. Ljungberg and Tawfik will start their new assignments during February 2021.
CanSino Bio chief satisfied with ongoing Stage III clinical trials of COVID-19 vaccine in Pakistan
Pakistan
Pakistan s ambassador to China Moin Ul Haque. File photo
BEIJING: Pakistan s ambassador to China Moin Ul Haque on Wednesday informed the Chinese firm CanSino Biologics Inc that the country will be approaching the regulatory authorities to put measures for obtaining compliance of the coronavirus vaccine made by the pharmaceutical company.
The ambassador gave the assurance during a visit to the headquarters of Tianjin-based CanSino Biologics Inc. During the visit, Haque met with the company s Co-Founder, Chairman and CEO Yu Xuefeng .
The two officials expressed satisfaction at the Stage III clinical trials of CanSino COVID-19 vaccine candidate in Pakistan with local partner AJM Pharma.
(2)
CT-P59 (40mg/kg) treated patients reported reduced progression rates to severe COVID-19 by 54% for patients with mild-to-moderate symptoms and 68% for moderate patients aged 50 years and over
CT-P59 (40mg/kg) treated patients reported a significantly shortened time to clinical recovery ranging from 3.4 to 6.4 days quicker compared to placebo
A significant reduction of viral load compared to placebo was reported at Day 7 in patients treated with CT-P59; with CT-P59 receiving a positive safety profile and no drug-related serious adverse events reported
The preclinical data of CT-P59 against SARS-CoV-2, demonstrating a 100-fold reduction in viral load of SARS-CoV-2 and improved recovery time in animal models has been published in Nature Communications journal
Policymakers are urged to include government negotiation to reduce insulin prices
The Endocrine Society is calling on policymakers to include government negotiation as part of an overall strategy to reduce insulin prices in its updated position statement published today in
The Journal of Clinical Endocrinology & Metabolism.
More than 34 million Americans have diabetes, and another 88 million are at risk for developing the disease. The cost of insulin has nearly tripled in the past 15 years, and a lack of transparency in the drug supply chain has made it challenging to identify and address the causes of soaring costs.
Federal law currently prohibits Medicare, which accounts for a third of all drug spending, from negotiating directly with pharmaceutical companies over drug prices. Legislation empowering the government to negotiate lower insulin prices could save billions and provide more benefits to Medicare beneficiaries.
BeiGene announces Novartis collaboration on antibody By Liu Zhihua | chinadaily.com.cn | Updated: 2021-01-13 11:13 Share CLOSE Scientists discuss use of equipment at the central chemistry lab of BeiGene in Beijing in May 2017. [Photo provided to chinadaily.com.cn]
China-based biotechnology company BeiGene Ltd held a media conference in Beijing on Tuesday to announce its collaboration and license agreement with Swiss pharmaceutical company Novartis Pharma AG for development and commercialization of the cancer treatment tislelizumab.
The two companies have agreed to jointly develop BeiGene s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, the European Union, the United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan.